Table 5. Indications for lung transplant referral and listing in pulmonary vascular disease.
Referral |
NYHA class III–IV symptoms during escalating therapy |
Rapidly progressive disease |
Use of parenteral targeted PAH therapy |
Known or suspected PVOD or pulmonary capillary hemangiomatosis |
Listing |
NYHA class II–IV despite at least 3-month combination therapy including prostanoids |
CI <2 L/min/m2 |
mRAP >15 mmHg |
6MWD <350 m |
Significant hemoptysis, pericardial effusion, or progressive RHF |
NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; PVOD, pulmonary veno-occlusive disease; CI, cardiac index; mRAP, mean right atrial pressure; 6MWD, six-minute walk distance; RHF, right heart failure.